Ipsen to buy Albireo

Tuesday 10 January 2023
Country

France

Ipsen SA has announced a merger agreement with Albireo Pharma Inc which will give it a marketed product for the treatment of rare diseases affecting the liver. The acquisition is expected to provide immediate revenue from sales of Albireo’s lead drug Bylvay (odevixibat). However, given ongoing research and developments costs, it will be dilutive to Ipsen’s operating profit until the end of 2024.